BioCardia
Open
$0.86
Prev. Close
$0.86
High
$0.86
Low
$0.86
Market Snapshot
$9.63M
-1.2
-3.09
$58K
17
BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company is headquartered in Sunnyvale, California and currently employs 17 full-time employees. The company is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company is headquartered in Sunnyvale, California and currently employs 17 full-time employees. The company is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Recently from Cashu
BioCardia Progresses CardiAMP Therapy with FDA Designation and Medicare Reimbursement Strategies
BioCardia (Ticker: BCDA) has recently made notable strides in its CardiAMP Cell Therapy aimed at treating ischemic heart failure. During the first quarter earnings call, CEO Peter Altman emphasized th…
BioCardia Earnings Report: Key Insights on Cardiac Innovations and Future Growth Potential
BioCardia's Pivotal Upcoming Earnings Report: A Focus on Cardiac Innovations BioCardia is set to unveil its quarterly earnings report on November 12, 2025, a date that holds significant importance for…
Please provide the content you would like me to summarize.
Sure! Please provide the text you would like me to summarize.
BioCardia Stock Update: Request for Content to Summarize
I apologize, but it seems that there is no specific content provided for me to summarize. Please share the content you would like me to work with, and I will be happy to help!